Bavarian Nordic files chikungunya vaccine for approval in Brazil
Bavarian Nordic's Brazilian distribution partner, Eurofarma, has submitted a marketing authorisation application to Brazil's health regulator Anvisa for CHIKV VLP, the Danish vaccine company's chikungunya candidate. The filing covers active immunisation in individuals aged 12 and older and marks the first attempt to bring an approved chikungunya vaccine to the Latin American market at scale.
The submission follows an exclusive distribution agreement struck between the two companies in January 2026, under which Eurofarma holds responsibility for regulatory activities, commercialisation and in-country distribution while Bavarian Nordic remains the manufacturer and product supplier. Eurofarma also retains a right of first refusal on future chikungunya opportunities across the broader Latin American region.
The vaccine and the disease burden
CHIKV VLP is a single-dose, prefilled, adjuvanted virus-like particle recombinant protein vaccine. It contains no viral genetic material, making it non-infectious, and is reported to begin inducing protective immunity within one week of administration. The vaccine is already approved by the FDA, the European Commission, the MHRA, Swissmedic and Health Canada under the trade name VIMKUNYA.
Brazil's public health rationale for an expedited Anvisa review is considerable. In 2025, more than 500,000 chikungunya cases and nearly 200 associated deaths were recorded globally; Brazil accounted for more than half of both figures, according to data from the Pan American Health Organization. The disease also carries a significant chronic burden: an estimated 30 to 40 per cent of those infected develop joint pain and fatigue that can persist for months or years after acute infection. Underdiagnosis compounds the problem, with chikungunya frequently confused with dengue fever owing to overlapping symptoms.
Paul Chaplin, president and chief executive of Bavarian Nordic, said the Anvisa submission was "an important milestone in our strategy to expand access to our chikungunya vaccine beyond traditional travel markets and into regions where the disease poses a significant and recurring public health burden."
Market context and competitive positioning
The filing marks a strategic pivot for Bavarian Nordic, which has historically positioned CHIKV VLP as a travel vaccine for Western markets. Entering an endemic country through a well-established local partner addresses the distribution and reimbursement complexities that have slowed other vaccine launches in emerging markets.
Chikungunya vaccine development remains a relatively uncrowded field compared with other arboviruses. No chikungunya vaccine had received regulatory approval anywhere until 2023, and Bavarian Nordic's VIMKUNYA remains among a small number of candidates with broad regulatory clearance. A competing live-attenuated vaccine candidate has been in development at other organisations, but none currently holds approval in Brazil, giving Bavarian Nordic a potential first-mover advantage in the formal regulated market if Anvisa grants authorisation.
Eurofarma's scale, with operations across 24 countries, more than 13,000 employees and net revenues exceeding USD 2.24 billion in 2025, provides Bavarian Nordic with commercial infrastructure well beyond what the Danish company could realistically build independently in the region. The right-of-first-refusal clause across Latin America suggests both parties are positioning this as the first step in a broader regional rollout rather than a Brazil-only arrangement.
Anvisa's review timeline will be the immediate focus for investors; the regulator has in recent years moved to align review standards with international counterparts, which could support a comparatively swift assessment given the vaccine's existing approvals in the US, EU and UK.